Top Markets
#1 ADO Protocol ADO Protocol +329.06%
#2 GoPlus Security GoPlus Security +55.29%
#3 Starpower Starpower +49.28%
#4 The Black Bull The Black Bull +36.13%
#5 Nockchain Nockchain +33.90%
#6 Verus Coin Verus Coin +33.62%
#7 Tutorial Tutorial +33.08%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +31.73%
#9 GAIB AID GAIB AID +24.67%
#10 Fake World Assets Fake World Assets +21.93%
Coin of the day
ADO Protocol ADO Protocol
Настройки
Язык
Pусский
Валюта
USD
Тема
NuCana plc NuCana plc

NuCana plc

NCNA
Ранг среди акций #32773
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Цена акции
$1.51
Рыночная капитализация
$9.14M
Изменение (1 день)
-5.35%
Изменение (1 год)
-59.65%
Страна
GB
Торговля NuCana plc (NCNA)

Категория

Healthcare
Прибыль NuCana plc (NCNA)
Прибыль на 2026 TTM: 0
Согласно последним финансовым отчетам NuCana plc, текущая прибыль компании составляет 0. В 2026 году компания получила прибыль 0, равна прибыли за 2026, которая составила 0. Отображаемая прибыль на этой странице — это прибыль до уплаты процентов и налогов, или просто EBIT.
История прибыли компании NuCana plc с 2026 по 2026
Прибыль в конце каждого года
Год Прибыль Изменить
Недостаточно данных для указанных дат.
Прибыль схожих компаний или конкурентов
Компания Прибыль Разница в прибыли Страна
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE